Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(4 sites)
United States
Northwestern University Robert H Lurie Medical Research, Chicago, Illinois UK Markey Cancer Center, Lexington, Kentucky Advanced Molecular Imaging and Therapy, Glen Burnie, Maryland XCancer Omaha / Urology Cancer Center, Omaha, Nebraska